ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Esmya® 5 mg, comprimés:Gedeon Richter (Schweiz) AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
G03XB02 - UlipristalATC-DDD Version 2016. Source: WHO
G - Genito Urinary System and Sex Hormones
 
G03 - Sex Hormones and Modulators Of The Genital System

Other hormones, see H - Systemic hormonal preparations, excl. sex hormones and insulins.
Sex hormones used only in the treatment of neoplastic diseases (often selected strengths) are classified in L - Antineoplastic and immunomodulating agents.

The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability. The DDDs of depot preparations are calculated as the dose divided by the dosing interval.

G03X - Other Sex Hormones and Modulators Of The Genital System

This group comprises drugs modifying the genital functions, which cannot be classified in the preceding groups.
Tibolone is classified in G03DC.

G03XB - Progesterone Receptor Modulators

Mifepristone indicated for Cushingss syndrome is also classified in this group.
The combination package of mifepristone and misoprostol (oral or vaginal route) is classified in G03XB51.

The DDDs for mifepristone (G03XB01) and mifepristone, combinations (G03XB51) are based on the use in termination of pregnancy.
The DDD for the combination package is given as amount of mifepristone.

G03XB02 - Ulipristal
Concentr.Adm.RouteNote
 O 
2025 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home